Get the Stockscreener App
69.05
0.28%
-1.40
Dexcom Inc stock is traded at $69.05, with a volume of 132.70K.
It is down -0.28% in the last 24 hours and up +3.01% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$67.65
Open:
$67.65
24h Volume:
132.70K
Relative Volume:
0.02
Market Cap:
$26.92B
Revenue:
$4.30B
Net Income/Loss:
$571.50M
P/E Ratio:
48.34
EPS:
1.4285
Net Cash Flow:
$570.80M
1W Performance:
+0.60%
1M Performance:
+3.01%
6M Performance:
-18.65%
1Y Performance:
-15.54%
1-Day Range:
$67.30
$69.10
1-Week Range:
$65.19
$67.94
52-Week Range:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
69.03 | 26.38B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
128.32 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.31 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.39 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.47 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.58 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
How DexCom Inc stock performs in weak economy2025 Performance Recap & AI Enhanced Trading Signals - moha.gov.vn
Assessing DexCom (DXCM) Valuation As Shares Lag Over The Past Year - Yahoo Finance
DexCom, Inc.'s (NASDAQ:DXCM) Stock Been Rising: Are Strong Financials Guiding The Market? - Yahoo Finance
Who Owns Dexcom? Top Shareholders and Recent Insider Trades - TIKR.com
DexCom, Inc. $DXCM Shares Sold by Ethic Inc. - Defense World
Dexcom Stock in Focus: Quiet Rally, Mixed Signals and a Data?Driven Bet on Connected Diabetes Care - AD HOC NEWS
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Mobile Health (mHealth) Technologies and Global Markets Report 2025-2030 Featuring Leading CompaniesApple, Samsung, AT&T, Medtronic, Abbott, Koninklijke Philips N.V., and DexcomResearchAndMarkets.com - The AI Journal
DexCom Inc Stock Price Live, Charts & News - The Economic Times
The Truth About DexCom Inc: Why Everyone Is Suddenly Watching DXCM - AD HOC NEWS
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium - TradingView — Track All Markets
DexCom (NASDAQ:DXCM) & Avanos Medical (NYSE:AVNS) Head-To-Head Contrast - Defense World
Dexcom Stock Finds Its Range: What The Latest Drift, Data, And Deals Signal For 2026 - AD HOC NEWS
FDA says Dexcom issues correction for Dexcom G6 and G6 Pro software - marketscreener.com
E. Ohman J or Asset Management AB Raises Position in DexCom, Inc. $DXCM - MarketBeat
SWS Partners Purchases 19,073 Shares of DexCom, Inc. $DXCM - MarketBeat
Beacon Investment Advisory Services Inc. Trims Stock Position in DexCom, Inc. $DXCM - Defense World
Class Action Alert: Levi & Korsinsky Reminds DexCom (DXCM) Investors of December 26, 2025 Deadline - ACCESS Newswire
DexCom, Inc. Sued for Securities Law Violations – Investors - GlobeNewswire
DexCom, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before December 26, 2025 to Discuss Your RightsDXCM - Finviz
DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, - GlobeNewswire
DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline for Contacting the Firm - GlobeNewswire Inc.
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DXCM DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts DexCom, Inc. Investors to Participate in the Class Action Lawsuit - ACCESS Newswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Levi & Korsinsky Urges DexCom (DXCM) Shareholders to Act Before Lead Plaintiff Deadline December 26, 2025 - ACCESS Newswire
Lost Money on DexCom, Inc. (DXCM)? Join Class Action Before December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
December 26, 2025 Deadline: Join Class Action Lawsuit Against DexCom, Inc. (DXCM)Contact Levi & Korsinsky - ACCESS Newswire
Securities Lawsuit Alert: DexCom, Inc. (DXCM) InvestorsContact Levi & Korsinsky Before December 26, 2025 - ACCESS Newswire
DAVENPORT & Co LLC Increases Position in DexCom, Inc. $DXCM - MarketBeat
Lost Money on DexCom, Inc. (DXCM)? Urged to Join Class Action Before December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
DXCM ALERT: Securities Fraud Class Action Launched Against DexCom, Inc.December 26, 2025 Deadline - ACCESS Newswire
Investor Alert: Deadline Approaching to Join DexCom, Inc. (DXCM) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Class Action Lawsuit Filed: DexCom, Inc. (DXCM)Join by December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
Voya Investment Management LLC Sells 186,132,582 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom (DXCM): Reassessing Valuation After Class Action Lawsuits and New FDA Clearance for Smart Basal - Sahm
DXCM Investors Have Opportunity to Lead DexCom, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
An Intrinsic Calculation For DexCom, Inc. (NASDAQ:DXCM) Suggests It's 47% Undervalued - 富途牛牛
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT - GuruFocus
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Yahoo Finance
DexCom, Inc. (DXCM) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 26, 2025 Deadline - Stockhouse
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc.(DXCM) Shareholders - The Malaysian Reserve
December 26, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against DXCM - GlobeNewswire
Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained - ACCESS Newswire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DexCom, Inc. $DXCM Shares Sold by Congress Asset Management Co. - MarketBeat
Will FDA Smart Basal Approval and New Lawsuits Change DexCom's (DXCM) Product Quality Narrative? - Sahm
Dexcom G6 Glucose Monitors Lawsuit - Drugwatch.com
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):